
Cancer causes premature death and zzso often zzso zzso While zzso of survival is an obvious end point for new cancer drug approval, the US Food and Drug Administration zzso has also zzso end points that evaluate patient zzso In this article we discuss the end points, evidence, and analyses supporting cancer drug approvals based on evaluations of zzso signs and zzso With advice from the zzso Drug Advisory Committee zzso in the late 1970s and early 1980s, zzso determined that acceptable end points for cancer drug approval were survival or an improvement in the quality of a patient's life, zzso an improvement in zzso zzso This article summarizes 15 zzso cancer drug approvals based on patient symptom assessments and/or physical signs zzso to represent symptomatic zzso as the primary evidence of zzso These include painful bone events (three zzso zzso improvement in zzso zzso and zzso zzso zzso (six zzso the consequences zzso zzso zzso of zzso responses in zzso and zzso zzso zzso relief of pulmonary or zzso obstruction zzso zzso and one case each of symptom benefit in pancreatic cancer (also associated with survival zzso and pulmonary symptom benefit in lung zzso An zzso example of an individual patient benefit end point is discussed, though it did not lead to a drug approval (the zzso gel zzso zzso trial designs and analysis plans may allow greater reliance on morbidity assessments to support future cancer drug zzso Drug sponsors are encouraged to include symptom assessments in cancer clinical trials and to perform further research to improve zzso zzso The zzso routinely meets with sponsors at End of Phase 2 zzso to discuss drug development plans and the design of phase 3 zzso We encourage sponsors to request special protocol assessments zzso after meeting with the zzso to get written confirmation of the zzso of plans for assessing cancer morbidity and quality of life, including zzso end points, statistical analysis plans, and draft case report zzso 

